<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>15 Gynaecological cancers</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part20.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part22.htm">Далее &gt;</a></p><p style="padding-top: 3pt;padding-left: 49pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark20" class="s95" name="bookmark61">Chapter 15</a><a name="bookmark62">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 49pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_221.png"/></span></p><p style="padding-top: 4pt;padding-left: 49pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark20" class="h2">Gynaecological </a><h2 href="#bookmark20">cancers</h2></p><p class="s5" style="padding-top: 10pt;padding-left: 48pt;text-indent: 0pt;text-align: left;">Kate lankester and lavanya Vitta</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 13pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">15.1 <span class="h4">Introduction</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Gynaecological cancers account for only 5% of cancer cases in the UK. However, there has been an increasing incidence in older age groups, with the exception of invasive cervical carcinoma, which has been declining since 1990, and va- ginal cancer, which has remained stable. Imaging has become integrated into the management pathways for patients with suspected gynaecological malignancy. Imaging investigations inform treatment decisions, although evidence that they alter management in ways that impact on outcome measures, such as disease- free and overall survival, is still lacking. Combined molecular and anatomical imaging modalities such as <span class="s22">18</span>F-fluorodeoxyglucose positron emission tomography/ computed tomography (FDG PET/CT) are becoming more accessible. Imaging also aids radiotherapy planning and is used during treatment to match bony and soft-tissue anatomy to the original planning CT scan to ensure accurate treatment set-up.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">15.2 <span class="h4">Ovarian cancer</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Ovarian cancer is treated with a combination of surgery and chemotherapy. Radiotherapy has only a limited role but can be useful in the palliative setting, for ex- ample for a symptomatic pelvic mass or if a patient develops brain metastases. Imaging for ovarian cancer is not discussed further in this chapter.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">15.3 <span class="h4">Uterine cancer</span></p><p class="s97" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">15.3.1 <span class="s29">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Uterine cancer is the fourth most common malignancy in UK women, with an incidence of ~30 per 100,000. The majority are adenocarcinomas arising from the endometrium. Most women (94%) are over the age of 50 years. Early stage presen- tation is the norm, reflected by an overall five-year survival of 79%. However, an improving survival rate has been offset by a rise in incidence since the early 1990s. Other uterine cancers such as carcinosarcomas (malignant mixed Müllerian tu- mours) and malignant myometrial tumours (e.g. leiomyosarcoma) are uncommon or rare.</p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">15.3.2 <span class="s29">Diagnosis and staging</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Staging is defined by the International Federation of Gynaecology &amp; Obstetrics (FIGO) system (2009) shown in Table 15.1). Endometrial cancer typically presents with postmenopausal bleeding (PMB), seen in 90%, resulting in early detection. Initial investigation often utilizes transvaginal ultrasound (TVUS) to establish the endomet- rial thickness. It has been shown to be a cost-effective means to determine the need for sampling, as an endometrial thickness of ≤4 mm indicates a low risk of malignancy, with a sensitivity of 90.6%; which can be maximized to 96.9% using a threshold of 3 mm. Although TVUS is able to locally stage endometrial tumours with accuracy similar to MRI, it is usual practice for patients to undergo MRI staging once a cancer diagnosis has been made.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MRI is the preferred modality for treatment planning: to assess the depth of myometrial invasion, cervical stromal invasion, lymph node involvement, and ad- vanced disease.<span class="s22">1 </span>Diffusion-weighted MRI (DWI) improves the differentiation of ma- lignant from benign pathologies<span class="s22">2 </span>and also improves the accuracy of assessment of depth of myometrial invasion.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The endometrium, junctional zone, and myometrium have high, low, and inter- mediate signal intensity, respectively, on T2-weighted MRI. This differential anatomy allows substaging of stage I tumours. Endometrial cancer initially penetrates the junctional zone to invade the myometrium, which can be depicted with an accuracy of 90–95% on fusion MRI combining T2-weighted and DWI. DWI measures the random</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 11pt;text-indent: 0pt;text-align: justify;">Table 15.1 <span class="s52">FiGo staging (2009) for carcinoma of the endometrium</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3622pt" cellspacing="0"><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage i</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">tumour confined to the uterus</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">ia</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">≤50% myometrial invasion</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iB</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">≥50% myometrial invasion</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage ii</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">tumour invades cervical stroma, but does not extend beyond the uterus</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iii</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">local and/or regional spread of the tumour</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiia</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">tumour invades the uterine serosa and/or adnexae</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiiB</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Vaginal and/or parametrial involvement</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiiC</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Metastasizes to pelvic and/or para-aortic lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiiC1</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">pelvic lymph node involvement</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiiC2</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">para-aortic lymph node involvement, (with or without pelvic lymph nodes)</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iV</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">tumour invades bladder and/or bowel mucosa, and/or distant metastases</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iVa</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">tumour invasion of bladder and/or bowel mucosa</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iVB</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;padding-right: 16pt;text-indent: 0pt;line-height: 111%;text-align: left;">Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes</p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 109%;text-align: left;">adapted with permission from pecorelli s, ‘Revised FiGo staging for carcinoma of the vulva, cervix, and endometrium’, <span class="s83">International Journal of Gynecology &amp; Obstetrics, </span>Vol. 105, issue 2, pp. 103–4. Copyright</p><p class="s14" style="padding-left: 11pt;text-indent: 0pt;line-height: 8pt;text-align: left;">© 2009 John Wiley &amp; sons.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 82pt;text-indent: 0pt;text-align: left;"><span><img width="223" height="225" alt="image" src="Image_222.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 15.1 <span class="s52">sagittal t2-weighted MRi of a large endometrial cancer invading the cervical stroma—FiGo stage ii.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Brownian motion of water molecules in tissues and can aid differentiation between tu- mour and normal tissue, as highly cellular tumours and swollen cells show restricted diffusion and a lower diffusion coefficient. The tumour may grow caudally to invade the mucosa or stroma of the cervix (FIGO stage II) (Figure 15.1).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Dynamic contrast enhanced MR and DWI is able to define cervical involvement with an accuracy of imaging 95%.<span class="s22">3 </span>Difficulties in tumour staging arise when the junctional zone is indistinct or abnormal (as in adenomyosis) and when the myome- trium is thin. Gadolinium enhancement can be of particular value in these cases as the tumour typically enhances less than the normal myometrium, improving tumour to muscle contrast.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Uterine carcinoma usually metastasizes initially to the loco-regional lymph nodes. However, anatomical imaging remains limited in its ability to stage nodal disease and depends mainly on the presence of enlarged lymph nodes. Detection of metastases within normal sized lymph nodes is limited. If the nodes look normal on imaging, then tumour grade and the extent of myometrial invasion may be used to stratify pa- tients into risk groups in order to decide whether lymphadenectomy is needed for sta- ging purposes.<span class="s22">4 </span>Sentinel lymph node sampling can be used to detect involved lymph nodes peri-operatively by injecting a blue dye or radiotracer.</p><p style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">MRI is also effective where advanced disease is clinically suspected (Figure 15.2).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Uterine sarcomas are rare tumours, comprising approximately 3–7% of all uterine malignancies.<span class="s22">5 </span>They are subdivided into leiomyosarcomas, carcinosarcomas (ma- lignant mixed Müllerian tumours), and endometrial stromal tumours. The diag- nosis is established histologically for uterine leiomyosarcomas as there is no pelvic imaging modality that can reliably differentiate between a leiomyoma (benign) and a uterine leiomyosarcoma (malignant). They appear similar on imaging: both are focal masses within the uterus and can have central necrosis. If a sarcoma is suspected on</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="380" height="189" alt="image" src="Image_223.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 15.2 <span class="s52">sagittal (a) and para-axial (b) t2-weighted MRi of an advanced endometrial cancer extending through the anterior uterine serosa to invade the sigmoid colon (arrows) confirmed on histology—FiGo stage iVa.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">imaging or proven pathologically, a staging body CT is recommended as these tu- mours have a greater propensity for metastasizing to the lungs. Both leiomyomas and leiomyosarcomas are known to show focal uptake of 18 FDG on PET scan- ning and demonstrate restricted diffusion on DWI and ADC (Apparent Diffusion Coefficient) maps (Figure 15.3).</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">15.3.3 <span class="s29">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Surgery is the primary treatment for uterine cancer, which comprises a total laparoscopic hysterectomy and bilateral salpingo-oophorectomy, as well as a pelvic lymphadenectomy in higher risk groups. To aid decision making regarding adjuvant treatment, patients can be stratified into risk groups (low, intermediate, high-intermediate, high, and advanced) depending on tumour stage, grade, and the presence of multifocal lymphovascular space invasion.<span class="s22">4 </span>Adjuvant radiotherapy to the pelvis is recommended to reduce the risk of local recurrence for patients with stage I disease with poor prognostic features (deep myometrial invasion, grade 3, multifocal lymphovascular space invasion), and for pa- tients with higher stages.<span class="s22">4 </span>Adjuvant brachytherapy to the vaginal vault is recommended on its own for intermediate risk patients or in conjunction with pelvic radiotherapy for patients who have cervical involvement.<span class="s22">4 </span>Guidelines and imaging atlases have been de- veloped to aid outlining of organs at risk (OAR) and clinical target volumes for treatment with Intensity Modulated Radiotherapy (IMRT).<span class="s22">6,7 </span>Patients are planned using a CT scan with IV contrast (to help distinguish blood vessels from bowel loops), with reference to the pre-op MRI imaging. Patients are scanned and treated with a comfortably full bladder and bowel preparation (e.g. sodium citrate enemas) may be used to minimize internal organ movement.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">Imaging during radiotherapy (e.g. cone beam CT imaging) is used to ensure ac-</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">curate set-up and adequate target coverage, by matching soft tissue and bony anatomy to the planning CT scan images. Image quality is not as good as diagnostic CT imaging</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="171" height="171" alt="image" src="Image_224.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="202" height="171" alt="image" src="Image_225.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="201" height="171" alt="image" src="Image_226.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 15.3 <span class="s52">sagittal t2-weighted image (a) showing a large heterogenous mass within the uterus with ill-defined margins, confirmed as leiomyosarcoma at histology. Corresponding axial DWi (b) and aDC (c) images show restricted diffusion within the mass.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">due to the inherent geometry of the system (increased scatter) causing increased noise, resulting in low contrast resolution. A bladder ultrasound scan before the radiotherapy planning CT scan and before treatment to ensure consistency of bladder filling may also be useful.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">15.3.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">As uterine cancer is generally a surgically treated disease, post-treatment imaging is reserved for those patients who present with inoperable disease where palliative treat- ment (radiotherapy and/or chemotherapy) and response monitoring is deemed appro- priate. Relapse can affect many sites—the most frequent being the vaginal vault, pelvic lymph nodes, peritoneum, and the lungs. Patient education is an important part of post-treatment surveillance as the majority of relapses are symptomatic, particularly those at the vaginal vault (causing vaginal bleeding). If local recurrence is discovered, or disseminated disease clinically suspected, body imaging, usually with CT (and/or MRI for assessment of local recurrence) is undertaken to establish the extent of dis- ease for treatment planning. PET/CT may be useful where a radical surgical approach is proposed.</p><p class="s96" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">15.4 <span class="h4">Cervical cancer</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">15.4.1 <span class="s29">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The incidence of invasive cervical cancer in the UK is 10 per 100,000. The majority are squamous cell carcinomas, though adenocarcinomas, adenosquamous carcinomas, and other rare histological types may also occur.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">15.4.2 <span class="s29">Diagnosis and staging</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The FIGO staging (2018) for cervical cancer is presented in Table 15.2. Previous ver- sions were based mainly on clinical examination, but the 2018 staging system has been revised to allow imaging and pathological findings to assign stage. The TNM staging system is also useful if using MRI to stage as it separates out primary tumour (T) from regional nodal involvement (N).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">If not detected at screening, presentation with vaginal bleeding and discharge is usual. Gynaecological examination, colposcopy, and biopsy are used to establish the diagnosis.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Most of the published literature regarding cervical cancer imaging refers to the evaluation of patients with macroscopically visible tumours (FIGO ≥IB). (By defin- ition, stage IA cancers are microscopic, so cannot be reliably detected by any of the available imaging modalities.)</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Imaging, especially MRI, has been shown to be superior to clinical examination alone for correctly evaluating cervical carcinoma stage (Figure 15.4 demonstrates a stage IB3 tumour). A meta-analysis reported a pooled sensitivity for detection of parametrial invasion of 84% versus 40% for MRI, compared to clinical examination (specificity was similar: 92% vs. 93%).<span class="s22">8 </span>The preferred imaging method for local cervical cancer evaluation is MRI but CT is equally effective for evaluation of extra-uterine spread of the disease. PET-CT shows high diagnostic performance for the detection of tumour relapse and metastatic lymph nodes.<span class="s22">9</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Imaging aids treatment planning in terms of choice of treatment between surgery and radiotherapy. Standard surgical management of cervical cancer is a radical hys- terectomy plus pelvic lymphadenectomy. However, fertility-sparing surgery may be possible for small stage I tumours: a cone biopsy alone for a stage IA tumour or a rad- ical trachelectomy (which removes the cervix and upper vagina, leaving the uterine body <i>in situ</i>) for a small IB tumour. Endovaginal MRI, although not widely available, may be useful in selecting patients for trachelectomy by improving accuracy in staging, particularly where early parametrial invasion is suspected on external coil imaging.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For stage ≥IB tumours, decisions regarding whether a patient should be offered either surgery or radical chemoradiation depend on tumour size, the presence of parametrial invasion, and whether regional lymph nodes are involved. MRI can accur- ately exclude parametrial invasion, with a negative predictive value ranging from 94% to 100%.<span class="s22">9 </span>An intact hypointense stromal ring around the cervix on T2-weighted axial imaging represents the main sign for excluding parametrial invasion. DWI further improves the assessment of parametrial invasion when it is added to conventional T2-weighted MRI. DWI also improves the detection of lymph nodal metastases.</p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Table 15.2 <span class="s52">FiGo staging for cervical cancer</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6694pt" cellspacing="0"><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage i</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;padding-right: 16pt;text-indent: 0pt;line-height: 111%;text-align: left;">the carcinoma is strictly confined to the cervix (extension to the corpus would be disregarded)</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">ia</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 111%;text-align: left;">invasive carcinoma that can be diagnosed only by microscopy, with maximum depth of invasion &lt;5 mm</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">ia1</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Measured stromal invasion of &lt;3 mm in depth</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">ia2</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Measured stromal invasion of ≥3 mm and &lt;5 mm in depth</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iB</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;padding-right: 16pt;text-indent: 0pt;line-height: 111%;text-align: left;">invasive carcinoma with measured deepest invasion ≥5 mm (greater than stage ia), lesion limited to the cervix uteri</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iB1</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 111%;text-align: left;">invasive carcinoma ≥5 mm depth of stromal invasion, and &lt;2 cm in greatest dimension</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iB2</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">invasive carcinoma ≥2 cm and &lt;4 cm in greatest dimension</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iB3</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">invasive carcinoma ≥4 cm in greatest dimension</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage ii</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;padding-right: 16pt;text-indent: 0pt;line-height: 111%;text-align: left;">the carcinoma invades beyond the uterus, but has not extended onto the lower third of the vagina or to the pelvic wall</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iia</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 111%;text-align: left;">involvement limited to the upper two-thirds of the vagina without parametrial invasion</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iia1</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">invasive carcinoma ≤4 cm in greatest dimension</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iia2</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">invasive carcinoma &gt;4 cm in greatest dimension</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiB</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">With parametrial involvement, but not up to the pelvic wall</p></td></tr><tr style="height:36pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iii</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 111%;text-align: left;">the carcinoma involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or non-functioning kidney and/or involves pelvic and/or para-aortic lymph nodes</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiia</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 111%;text-align: left;">the carcinoma involves the lower third of the vagina, with no extension to the pelvic wall</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiiB</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 111%;text-align: left;">extension to the pelvic wall and/or hydronephrosis or non-functioning kidney (unless known to be due to another cause)</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiiC</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;padding-right: 16pt;text-indent: 0pt;line-height: 111%;text-align: left;">involvement of pelvic and/or para-aortic lymph nodes, irrespective of tumour size and extent</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiiC1</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">pelvic lymph node metastasis only</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiiC2</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">para-aortic lymph node metastasis</p></td></tr><tr style="height:36pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iV</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;padding-right: 4pt;text-indent: 0pt;line-height: 111%;text-align: left;">the carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum (a bullous oedema, as such, does not permit a case to be allotted to stage iV)</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iVa</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">spread to adjacent pelvic organs</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iVB</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">spread to distant organs</p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 108%;text-align: justify;">Reproduced with permission from Bhatla n et al. ‘Revised FiGo staging for carcinoma of the cervix uteri’, <span class="s83">International Journal of Gynecology &amp; Obstetrics, </span>Vol. 145, issue 1, pp. 129–135. Copyright © 2019 John Wiley &amp; sons.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="222" alt="image" src="Image_227.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 15.4 <span class="s52">axial (a) and sagittal (b) t2-weighted MRi in the anterior lip of the cervix with a thin rim of intact low signal cervix shown by arrows—stage iB3.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The addition of DWI may increase the diagnostic performance of MRI compared with PET/CT. It is reported that MRI including the DWI sequences is more precise than FDG PET/CT for detecting pelvic lymph node metastases, with a sensitivity, spe- cificity, and diagnostic accuracy of 67%, 84%, and 81% compared to 33%, 92%, and 81% for PET/CT; although the differences were not as pronounced for para-aortic lymph nodes.<span class="s22">10 </span>Although the addition of DWI clearly improves sensitivity of MRI for the detection of nodal metastases, PET/CT still has a higher specificity of up to 97%.<span class="s22">11 </span>Especially in cases of advanced disease, PET/CT has a high sensitivity (75–100%) and specificity (87–100%)<span class="s22">9 </span>and can help demonstrate sites of unexpected disease such as supraclavicular lymph nodes. However, neither PET/CT nor MRI is sufficiently ac- curate to replace lymphadenectomy (or biopsy) as the definitive assessment of lymph node status.<span class="s22">10,11</span></p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">15.4.3 <span class="s29">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">If a cervical cancer is too advanced for a radical hysterectomy (e.g. stage IB3 or above), then radical radiotherapy with concomitant chemotherapy (chemoradiation) is re- commended. Radical radiotherapy comprises external beam radiotherapy followed by intrauterine brachytherapy. Guidelines (e.g. for the substitute EMBRACE II trial) have been developed which define clinical target volumes for the primary tumour and the pelvic nodes and give recommendations regarding appropriate CTV-PTV margins for both conventional 3D radiotherapy and IMRT. Image fusion with the diagnostic MRI scan may help delineate the GTV.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In some patients, the uterus is very mobile and its position varies depending on the degree of bladder filling. As described in section 15.3.3, measures to minimize internal organ movement (by treating with a comfortably full bladder and using enemas to re- duce rectal filling) and imaging during treatment to ensure consistent bladder filling</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="297" alt="image" src="Image_228.gif"/></span></p><p class="s52" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 112%;text-align: left;"><span class="s24">Fig. 15.5 </span>MRi pelvis in sagittal plane with intra-uterine tube and vaginal ovoids, rectal retractor <span class="s121">in situ </span>for brachytherapy. Bladder catheter balloon and vaginal gauze packing also shown.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">are important to ensure accurate treatment, particularly for IMRT. Some centres are able to create a series of radiotherapy plans (with varying bladder volumes) and so, with daily image guidance, select the best ‘plan of the day’. This approach enables a de- crease in CTV-PTV margins and consequent reduction of dose to the bowel, rectum, and bladder.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A repeat MRI scan performed during the final week of external beam radiotherapy is useful to aid planning for brachytherapy.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For brachytherapy, the advent of MRI- and CT-compatible applicators means that 3D treatment planning is now possible as cross-sectional imaging can be performed with the applicators <i>in situ</i>. Recommendations for the definition and delineation of the ‘high-risk CTV’ have been published by the ICRU (report 89) and the EMBRACE II group.<span class="s22">12,13 </span>3D planning, particularly with T2-weighted MRI, allows tumour dose escal- ation, while maintaining dose to bladder, bowel, and rectum within tolerance levels.<span class="s22">13 </span>MRI is superior to CT as, while OAR can be clearly identified on CT images, MRI provides more accurate tumour definition (Figure 15.5).<span class="s22">14</span></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">15.4.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Following chemoradiation, MRI is repeated at three months to assess treatment re- sponse. If the cervix demonstrates uniform low signal, residual tumour is effectively excluded. A residual mass is usually a sign of persistent disease. However, persistent</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 116pt;text-indent: 0pt;text-align: left;"><span><img width="149" height="249" alt="image" src="Image_229.jpg"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 15.6 <span class="s52">Coronal FDG pet/Ct image showing an avid left common iliac lymph node in a patient with relapsed cervical cancer.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">high signal in the cervix is more problematic for distinction between residual disease and radiation effect, usually resulting in multidisciplinary discussion as to whether follow-up imaging (e.g. after another three months) or biopsy is most appropriate.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Depending on the results of MRI ± biopsy, CT may be utilized to evaluate poten- tial distant sites. FDG PET/CT may be a useful adjunct or replacement to anatom- ical imaging as it has the potential to differentiate local recurrence from fibrosis, to more accurately detect distant metastases and to alter management in a significant proportion of patients. However, to date, evidence for the addition of PET/CT to MRI and CT in women with suspected recurrent/persistent cervical cancer and in asymptomatic women as surveillance remains scarce. Nevertheless, it has been re- commended for patients with a local recurrence prior to considering a pelvic exen- teration (Figure 15.6).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">15.5 <span class="h4">Vaginal cancer</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">15.5.1 <span class="s29">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Vaginal cancers are rare, comprising &lt;1% of gynaecological malignancies. The inci- dence increases with age, with 38% arising in patients who are 75 or older in the UK in 2013–2015. The majority are squamous cell carcinomas, though rarely vaginal melan- omas may occur. Secondary vaginal cancers are more common than primary vaginal cancers and most vaginal metastases occur by means of direct spread from the cervix, uterus, or rectum. Five-year survival has improved across all age groups and was 64% for 2009–2013. Pelvic examination continues to be the most important tool for evalu- ation of the local extent of the disease, but imaging is required to detect lymph node involvement, the extent of tumour infiltration, and metastatic spread.</p><p class="s97" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">15.5.2 <span class="s29">Diagnosis and staging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Clinical presentations include discharge, bleeding, itching, and dyspareunia. Initial in- vestigation comprises an examination under anaesthetic and biopsy. Staging is defined by the FIGO system (2009) (Table 15.3). MRI (Figure 15.7) is able to depict the ma- jority of tumours and in doing so can aid treatment planning by evaluating the size, location, and local extent of vaginal tumours and demonstrating the degree of lymph node involvement. The differential anatomy of the three vaginal layers is best appre- ciated on T2-weighted images: vaginal mucosa is hyperintense; the submucosa and muscularis layers are hypointense; and the adventitial layer is hyperintense. The tu- mour is best assessed on T2-weighted images and shown as intermediate to high signal abnormality. Contrast enhanced T1-weighted fat saturated sequences may improve accuracy. MRI is superior for defining the anatomical relationships of the primary tu- mour, whilst FDG PET/CT will be more accurate for detection of metastatic disease and also provide prognostic information—which may have a particular bearing when local radical treatment is contemplated<b>.</b></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">15.5.3 <span class="s29">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiotherapy is usually recommended for vaginal cancer, enabling organ preservation. As vaginal cancer is rare, there is limited data regarding the benefit of chemoradiation, but it is thought reasonable to extrapolate from the cervical cancer data and weekly cisplatin is used in combination with radiotherapy for patients with a good perform- ance status. For the phase II boost, a brachytherapy boost (with a vaginal cylinder +/</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">- interstitial needles) may be appropriate. As with cervical and endometrial cancer radiotherapy planning, a diagnostic MRI scan aids outlining the primary tumour and regional nodes. MRI also guides planning for a phase II brachytherapy boost— particularly if interstitial needles are used in addition to a vaginal cylinder.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">15.5.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Once again, extrapolating cervical cancer practice to the rare vaginal cancer group, MRI will aid clinical assessment of treatment response and local recurrence with the</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Table 15.3 <span class="s52">FiGo staging for vaginal cancer</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6694pt" cellspacing="0"><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">i</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 16pt;text-indent: 0pt;text-align: left;">tumour confined to the vaginal wall</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">ii</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 16pt;text-indent: 0pt;text-align: left;">tumour invades paravaginal tissues but does not extend to pelvic wall</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iii</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 16pt;text-indent: 0pt;text-align: left;">tumour extends to pelvic wall</p></td></tr><tr style="height:26pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iVa</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 16pt;padding-right: 10pt;text-indent: 0pt;line-height: 111%;text-align: left;">tumour invades mucosa of the bladder or rectum and/or extends beyond the true pelvis</p></td></tr><tr style="height:15pt"><td style="width:28pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iVB</p></td><td style="width:295pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 16pt;text-indent: 0pt;text-align: left;">Distant metastasis</p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 108%;text-align: left;">adapted with permission from ‘Current FiGo staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia’. <span class="s83">International Journal of Gynecology &amp; Obstetrics</span>, Vol.105, issue 1, pp.3–4. Copyright © 2009 John Wiley &amp; sons.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="297" alt="image" src="Image_230.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 15.7 <span class="s52">sagittal t2-weighted MRi of a stage i vaginal cancer.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">attendant difficulties of distinguishing tumour from fibrosis—where FDG PET/CT and biopsy are likely to be useful adjuncts.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">15.6 <span class="h4">Vulval cancer</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">15.6.1 <span class="s29">Clinical background</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Vulval cancers are also rare (&lt;1% of cancers in women). It is strongly related to age, with 44% of cases arising in women aged 75 and above. Overall five-year survival is 64%; 90% of vulval cancers are squamous cell carcinomas. The vast majority are treated surgically with a radical vulvectomy +/- inguinal lymph node sampling or resection.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">15.6.2 <span class="s29">Diagnosis and staging</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Clinical presentation is typically with localized soreness, irritation, and a lump or ulcer. Tumours may also be detected during surveillance of vulval intra-epithelial neoplasia (VIN) or lichen sclerosis. Staging is defined by the FIGO system (2009) (Table 15.4).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The primary tumour is assessed clinically but cross-sectional imaging can help sta- ging of the tumour, assessing extent of disease, and selecting operable versus inoper- able patients (Figure 15.8).</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">15.6.3 <span class="s29">Imaging for radiotherapy planning</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The majority of cancers are managed surgically. Adjuvant radiotherapy is recom- mended for close margins and lymph node-positive disease. Inoperable locally</p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 15.4 <span class="s52">FiGo staging for vulval cancer</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6694pt" cellspacing="0"><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage i</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">tumour confined to the vulva</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">ia</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;padding-right: 12pt;text-indent: 0pt;line-height: 111%;text-align: left;">lesions ≤2 cm in size, confined to the vulva or perineum and with stromal invasion ≤1.0 mm, no nodal metastasis</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iB</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;padding-right: 12pt;text-indent: 0pt;line-height: 111%;text-align: left;">lesions &gt;2 cm in size or with stromal invasion &gt;1.0 mm, confined to the vulva or perineum, with negative nodes</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage ii</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;padding-right: 12pt;text-indent: 0pt;line-height: 111%;text-align: left;">tumour of any size with extension to adjacent perineal structures (the lower third of the urethra or the vagina or the anus) with negative nodes</p></td></tr><tr style="height:36pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iii</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;padding-right: 8pt;text-indent: 0pt;line-height: 111%;text-align: left;">tumour of any size with or without extension to adjacent perineal structures (the lower third of the urethra or the vagina or the anus) with positive inguino-femoral lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiia</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">(i) With 1 lymph node metastasis (≥5 mm), or</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">(ii) 1–2 lymph node metastasis(es) (&lt;5 mm)</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiiB</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">(i) With 2 or more lymph node metastases (≥5 mm), or</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">(ii) 3 or more lymph node metastases (&lt;5 mm)</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iiiC</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">With positive nodes with extracapsular spread</p></td></tr><tr style="height:26pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">stage iV</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;padding-right: 12pt;text-indent: 0pt;line-height: 111%;text-align: left;">tumour invades other regional (the upper two-thirds of the urethra or the vagina), or distant structures</p></td></tr><tr style="height:36pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iVa</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">tumour invades any of the following:</p><p class="s99" style="padding-top: 1pt;padding-left: 14pt;padding-right: 12pt;text-indent: -5pt;line-height: 111%;text-align: left;">(i) upper urethral and/or vaginal mucosa, bladder mucosa, rectal mucosa, or fixed to pelvic bone, or</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">(ii) fixed or ulcerated inguino-femoral lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">iVB</p></td><td style="width:286pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">any distant metastasis including pelvic lymph nodes</p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 109%;text-align: left;">Reproduced with permission from pecorelli s, ‘Revised FiGo staging for carcinoma of the vulva, cervix, and endometrium’, <span class="s83">International Journal of Gynecology &amp; Obstetrics</span>, Vol. 105, issue 2, pp. 103–4. Copyright</p><p class="s14" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">© 2009 John Wiley &amp; sons.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="382" height="189" alt="image" src="Image_231.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 15.8 <span class="s52">(a) axial t2-weighted MRi of a vulval cancer, (b) axial MRi of the same patient showing a pathological left groin node.</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">advanced primary disease may be referred for radiotherapy. In these cases, an MRI scan of the pelvis will aid assessment of the extent of the primary tumour, and inguinal and pelvic lymph node involvement. As in vaginal cancer, with extrapolation from the cervical cancer data, weekly cisplatin is used in combination with radiotherapy for pa- tients with good performance status.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">As discussed above, preparation for the CT planning scan is important (e.g. a com- fortably full bladder). Clinician review prior to the CT planning scan is helpful—so that visible tumour, the introitus, and groin scars can be outlined with wire to aid target volume delineation. Consensus guidelines have been developed to aid outlining of the GTV and give recommendations regarding which areas should be included in the CTV.<span class="s22">15</span></p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">15.6.4 <span class="s29">Therapeutic assessment and follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Pathological staging determines completion or otherwise of resection and hence the need for further surgery or radiotherapy. Recurrence is usually clinically apparent.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">15.7 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Imaging is integral to the management of the majority of gynaecological cancer patients from diagnosis through treatment to follow-up.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Functional imaging, using both MRI and FDG PET/CT, plays a major role in all points of the patient care pathway, strengthening the case for ever closer collabor- ation between all members of the multidisciplinary team.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">References</p><p class="s74" style="padding-top: 5pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">1. <b>Nougaret S</b>, <b>Horta M</b>, <b>Sala E, et al. </b>(2019). Endometrial cancer MRI staging: updated guidelines of the European society of urogenital radiology. <i>European Radiology</i>, <b>29</b>(2): 792–805.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">2. <b>Addley H</b>, <b>Moyle P</b>, <b>Freeman S </b>(2017). Diffusion-weighted imaging in gynaecological malignancy. <i>Clinical Radiology</i>, <b>72</b>(11): 981–990.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">3. <b>Lin G</b>, <b>Huang YT</b>, <b>Chao A, et al. </b>(2017). Endometrial cancer with cervical stromal invasion: diagnostic accuracy of diffusion-weighted and dynamic contrast enhanced MR imaging at 3T. <i>European Radiology</i>, <b>27</b>(5): 1867–1876.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">4. <b>Concin N, Matias-Guiu X, Vergote I , et al. </b>(2021). ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Int J Gynecol Cancer, </i><b>31</b>(1): 12–39.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">5. <b>Mbatani N</b>, <b>Olawaiye AB</b>, <b>Prat J </b>(2018). Uterine sarcomas. <i>International Journal of Gynaecological Obstetrics</i>, <b>143</b>(2): 51–58.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">6. <b>Taylor A</b>, <b>Rockall AG</b>, <b>Powell ME </b>(2007). An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition. <i>Clinical Oncology </i>(Royal College of Radiologists), <b>19</b>(7): 542–550.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">7. <b>Gay HA</b>, <b>Barthold HJ</b>, <b>O’Meara E, et al. </b>(2012). Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. <i>International Journal of Radiation Oncology. Biology. Physics</i>, <b>83</b>(3): e353–362.</p><p class="s74" style="padding-top: 4pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">8. <b>Thomeer MG</b>, <b>Gerestein C</b>, <b>Spronk S</b>, <b>van Doorn HC</b>, <b>van der Ham E</b>, <b>Hunink MG </b>(2013). Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis. <i>European Radiology</i>, <b>23</b>(7): 2005–2018.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">9. <b>Sala E</b>, <b>Rockall AG</b>, <b>Freeman SJ</b>, <b>Mitchell DG</b>, <b>Reinhold C </b>(2013). The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. <i>Radiology</i>, <b>266</b>(3): 717–740.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">10. <b>Monteil J</b>, <b>Maubon A</b>, <b>Leobon S, et al. </b>(2011). Lymph node assessment with (18)F-FDG- PET and MRI in uterine cervical cancer. <i>Anticancer Research</i>, <b>31</b>(11): 3865–3871.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">11. <b>Choi HJ</b>, <b>Ju W</b>, <b>Myung SK</b>, <b>Kim Y (2010)</b>. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. <i>Cancer Science</i>, <b>101</b>(6): 1471–1479.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">12. ICRU (2016). Report 89: Prescribing, recording and reporting brachytherapy for cancer of the cervix <i>J ICRU</i>, <b>13</b>(1–2):NP.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">13. <b>Haie-Meder C, GYNAE GEC ESTRO working group </b>(2005). 3D image based concepts in brachytherapy for cervical cancer. <i>Gynecologic Oncology</i>, <b>99</b>(3, Suppl 1): S176.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">14. <b>Viswanathan AN</b>, <b>Dimopoulos J</b>, <b>Kirisits C</b>, <b>Berger D</b>, <b>Pötter R </b>(2007). Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy: results of a prospective trial and preliminary guidelines for standardized contours. <i>International Journal of Radiation Oncology. Biology. Physics</i>, <b>68</b>(2): 491–498.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">15. <b>Gaffney DK</b>, <b>King B</b>, <b>Viswanathan AN, et al. </b>(2016). Consensus recommendations for radiation therapy contouring and treatment of vulvar carcinoma. <i>International Journal of Radiation Oncology. Biology. Physics</i>, <b>95</b>(4):1191–1200.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part20.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part22.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
